[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-fibrosis":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,75,100,122,146,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":45,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100647234","phase-1-fapi-pet-imaging---an-exploratory-study-100647234",false,"NCT07705074","FAPI PET Imaging - An Exploratory Study","FAPI PET Imaging - a Multicentric Exploratory Evaluation","FAPIPET","Inclusion Criteria:\n\n* Written informed consent obtained and documented by the participant's signature.\n* Age ≥18 years at the time of consent.\n* Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol.\n* Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT\u002FMRI) to allow comparative evaluation.\n\nExclusion Criteria:\n\n* Severe claustrophobia that would preclude PET imaging.\n* Inability to remain still for the duration of the PET\u002FMR examination.\n* Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy.\n* Previous hypersensitivity reactions to radiotracer administration\n* Inability to understand the study information, for example due to language barriers.\n* Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).\n* Participants scheduled for PET\u002FMR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.","ALL","18 Years",{"count":20,"type":21},770,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study is testing a new imaging tracer called \\[18F\\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.\n\n\\[18F\\]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well.\n\nPeople who join this study will get one injection of the tracer into a vein, then have one PET\u002FCT or PET\u002FMR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed.\n\nThe study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Thyroid Pathology","Head and Neck Cancer (H&N)","Sinonasal Tract Tumor","Sarcoidosis","Thyroid Cancer","Breast Cancer","Hepatocellular Carcinoma (HCC)","Gastric Cancer (GC)","Pancreatic Cancer, Adult","Urothelial Carcinoma (UC)","Multiple Myeloma or Plasmacytoma","Mesothelioma","Hepatic Fibrosis","Endometriosis (Diagnosis)","Lung Fibrosis","Neck Node Metastasis","Prostate Cancer (CRPC)",[46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61],"[18F]FAPI-74","Fibroblast Activation Protein","FAP-targeted imaging","PET\u002FCT","Radiotracer","Diagnostic imaging","Multicentric study","Radiopharmaceutical","FAPI","FAPI-74","nuclear medicine","University Hospital Zurich","swiss multicenter trial","Cancer-associated fibroblast imaging","oncologic imaging","non-oncologic imaging","NOT_YET_RECRUITING","2026-07-09",{"date":65,"type":66},"2026-07-15","ACTUAL",{"date":68,"type":21},"2026-08",{"date":70,"type":21},"2029-09",{"name":72,"class":73},"Martin Huellner","OTHER",5,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100573806","home-based-pulmonary-rehabilitation-and-health-coaching-in-patients-with-fibrotic-interstitial-lung-disease-100573806","NCT06751069","Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease","Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease: A Prospective Pragmatic Randomized Waitlist-Controlled Trial","IInclusion Criteria:\n\n* F-ILD diagnosis, any disease subtype, active or prior medical treatment\n* \\>10% fibrosis on CT imaging\n* mMRC dyspnea score \\>1\n* All racial or ethnic categories, including non-English speakers (professional translators will be engaged to support screening, enrollment, and study participation)\n\nExclusion Criteria:\n\n* Inability to walk (orthopedic\u002Fneurologic\u002Fcardiac limitation causing immobility)\n* Cognitive impairment or inability to understand and follow instructions\n* Traditional center-based PR completed within 3 months of initial study recruitment\n* Transition to hospice or end-of-life care at the time of screening\n* Acute exacerbation at the time of screening",{"count":83,"type":21},460,[85],"NA","The purpose of this clinical trial is to determine the impact of a home-based pulmonary rehabilitation program with health coaching on patient-reported respiratory-related quality of life and physical activity, as compared to usual care in patients with fibrotic interstitial lung disease.",[42,88],"Lung Interstitial Disease","RECRUITING","2026-03-18",{"date":92,"type":66},"2026-03-20",{"date":94,"type":66},"2025-03-03",{"date":96,"type":21},"2030-09-30",{"name":98,"class":73},"Mayo Clinic",4,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":109,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100611127","impact-of-airway-mucus-plugs-on-secondary-pulmonary-fibrosis-in-copd-patients-a-single-center-case-control-study-100611127","NCT07236541","Impact of Airway Mucus Plugs on Secondary Pulmonary Fibrosis in COPD Patients: A Single-Center Case-Control Study","Inclusion Criteria:\n\n* ① Age ≥ 18 years old;\n\n  * Planned radical resection for lung cancer, with postoperative pathological diagnosis of primary lung cancer;\n\n    * During surgery, non tumor lung tissue at a distance of ≥ 5 cm from the tumor edge can be obtained; ④ Case group: Preoperative pulmonary function examination confirmed diagnosis of COPD (FEV ₁\u002FFVC\\\u003C0.70); ⑤ Control group: Preoperative lung function was normal (FEV ₁\u002FFVC ≥ 0.70), with no history of COPD; ⑥ The subjects are able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n* ① Clear presence of other interstitial lung diseases (ILD) or idiopathic pulmonary fibrosis before or during surgery （IPF）、 Fibrosis after pneumoconiosis or tuberculosis;\n\n  * Active pulmonary infections (such as bacterial pneumonia, fungal infections, active tuberculosis);\n\n    * Having received neoadjuvant radiotherapy or chemotherapy, which may affect the morphology or molecular results of distal lung tissue; ④ Combined severe immunodeficiency or long-term systemic immunosuppressive therapy (such as glucocorticoids ≥ 20 mg\u002Fd, More than 4 weeks);\n\n      * Merge with other serious systemic diseases (such as advanced heart failure, end-stage renal disease), affecting study compliance or Survival expectation; ⑥ Pregnant or lactating women; ⑦ Refusing to sign the informed consent form or deemed unsuitable by the researcher to participate in the study.","89 Years",{"count":108,"type":21},20,"OBSERVATIONAL","Chronic obstructive pulmonary disease (COPD) is frequently accompanied by airway mucus plugs, which are closely associated with airflow obstruction, acute exacerbations, and increased mortality. However, whether mucus plugs contribute to secondary pulmonary fibrosis remains unclear. This single-center, prospective, case-control study aims to investigate the relationship between airway mucus plugs and lung fibrosis in patients with COPD undergoing lung cancer surgery.\n\nDuring surgery, distal non-tumorous lung tissues and airway mucus will be collected for histological and molecular analyses. Mucus plug burden will be quantified using AB-PAS staining, and fibrosis will be assessed using Masson staining. Expression of epithelial-mesenchymal transition (EMT) markers, fibrotic markers, and the mechanosensitive ion channel Piezo1 will also be measured. COPD patients (FEV₁\u002FFVC \\\u003C0.70) will be compared with non-COPD surgical controls.\n\nThe study aims to clarify whether mucus plugs are associated with increased fibrosis and to explore the potential involvement of mechanical-signaling pathways, including Piezo1 activation. Findings may provide new clinical and pathological evidence for mucus-induced fibrotic remodeling in COPD and help identify novel therapeutic targets.",[42],"2025-11-14",{"date":114,"type":66},"2025-11-19",{"date":116,"type":66},"2025-10-30",{"date":118,"type":21},"2026-06-30",{"name":120,"class":73},"Ming Zhong",1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":131,"studyType":109,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":121},"100468652","pulmonary-fibrosis-foundation-community-registry-100468652","NCT05382572","Pulmonary Fibrosis Foundation Community Registry","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form online\n2. Male or female, aged 18 or older\n3. Affected by PF as a member of at least one of the following cohorts:\n\n   1. An individual diagnosed with PF or ILD, including those who are post lung transplant, or\n   2. An individual who has cared (currently or in the past) for an individual with PF or ILD, and \u002F or\n   3. A family member (defined as parent, full or half-sibling, or child) of an individual with PF or ILD.\n4. Has internet access and a valid email address.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Primary residence or place of care is outside of the US.\n2. Inability or unwillingness of a participant to provide informed consent or comply with study protocol.\n3. Any condition or circumstance not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.\n4. Patients who were diagnosed with any of the below lung diseases. Similarly caregivers and family members associated with these diseases would be excluded.\n\n   * Sarcoid\n   * Lymphangioleiomyomatosis (LAM)\n   * Pulmonary alveolar proteinosis (PAP)\n   * Cystic fibrosis (CF)\n   * Amyloidosis",true,{"count":130,"type":21},10000,"5 Years","Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enroll and directly contribute information about their experience with PF to be compiled into a longitudinal data set for use by researchers.",[134,135,42,136],"Pulmonary Fibrosis","Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis","2025-04-08",{"date":139,"type":66},"2025-04-11",{"date":141,"type":66},"2022-07-11",{"date":143,"type":21},"2027-07-01",{"name":145,"class":73},"Pulmonary Fibrosis Foundation",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":128,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":157,"studyType":109,"phases":4,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":121},"100453964","immune-modulation-by-exosomes-in-covid-19-100453964","NCT05191381","Immune Modulation by Exosomes in COVID-19","Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19","IMECOV19","Inclusion Criteria:\n\n* Critically ill COVID-19 patients with lung dysfunction\n* COVID-19 WHO severity degree \\>= 4, ARDS (WHO Definition 13 March 2020)\n* Body weight \\> 50 kg\n* Informed consent\n\nExclusion Criteria:\n\n* Pregnant or breast feeding women","90 Years",{"count":156,"type":21},40,"12 Months","Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.",[160,161,162,42],"COVID-19","Critical Illness","Hypercytokinemia",[160,164,162,165,166,167,168,169],"Critical illness","Exosomes","Mesenchymal stem cells","Tissue reconstitution","Immune modulation","Sepsis","2024-01-16",{"date":172,"type":66},"2024-01-17",{"date":174,"type":66},"2021-12-22",{"date":176,"type":21},"2026-12-31",{"name":178,"class":73},"University of Ulm",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":15,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":121},"100530671","phase-2-role-of-the-fibroblast-activation-protein-fap-as-biomarker-of-fibrotic-lung-diseases-100530671","NCT06189820","Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases","Inclusion Criteria:\n\n* Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS\u002FERS\u002FJRS\u002FALAT Clinical Practice Guidelines\n\nExclusion Criteria:\n\n* Pregnant or nursing patients\n* Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.\n* Patients with an active lung neoplasm or any active neoplasm for blood samples",{"count":186,"type":21},70,[25],"To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET\u002FCT.",[134,42,136,190],"FAP",[192,190],"Pulmonary fibrosis","2023-12-18",{"date":195,"type":66},"2024-01-05",{"date":197,"type":66},"2023-03-09",{"date":199,"type":21},"2027-03-09",{"name":201,"class":73},"Erasme University Hospital"]